



News Release

NORGINE ACHIEVES DOUBLE-DIGIT GROWTH IN 2002

Sales by the Norgine Group of companies reached € 118 million in 2002, a 10% increase over 2001 and the sixteenth consecutive year in which double-digit growth has been achieved. The leading product, Movicol, saw sales increase to € 42.5 million. Other products showing significant growth in 2002 included Klean Prep, Fivasa and Nortussine. Sales of older products, such as Normacol and Pyralvex, remained stable.

Significant increases in sales were achieved in all of Norgine's European operations. Particularly strong growth was experienced in Germany, Belgium, Italy and throughout Scandinavia. The company continued to increase the size of its European field force during 2002.

In 2002 Norgine also completed its first partnering deal in the USA. Two products have been licensed to Prometheus who will be responsible for obtaining product registrations and the subsequent sales and marketing.

Commenting on these results Peter Stein, Managing Director of Norgine International said "2002 was another highly successful year for Norgine and further strengthened our position as one of the only speciality pharmaceutical companies with a truly pan-European presence. In 2003 Norgine will continue to invest in its R&D portfolio, as well as in its people and manufacturing facilities. The company expects to continue its recent history of growth above the average for the industry"

Norgine is a research based pharmaceutical company with a direct presence throughout Western Europe. Norgine is developing a pipeline of innovative pharmaceutical products addressing serious unmet medical needs with a focus on gastroenterology and hepatology. Additional information about Norgine can be found at www.norgine.com

- ends -

Date: 29th January 2003